Immunotherapy in Extensive-Stage Small Cell Lung Cancer

Curr Oncol. 2021 Oct 12;28(5):4093-4108. doi: 10.3390/curroncol28050347.ABSTRACTSmall cell lung cancer (SCLC) remains a poorly understood disease with aggressive features, high relapse rates, and significant morbidity as well as mortality, yet persistently limited treatment options. For three decades, the treatment algorithm of SCLC has been stagnant despite multiple attempts to find alternative therapeutic options that could improve responses and increase survival rates. On the other hand, immunotherapy has been a thriving concept that revolutionized treatment options in multiple malignancies, rendering previously untreatable diseases potentially curable. In extensive stage SCLC, immunotherapy significantly altered the course of disease and is now part of the treatment algorithm in the first-line setting. Nevertheless, the important questions that arise are how best to implement immunotherapy, who would benefit the most, and finally, how to enhance responses.PMID:34677265 | PMC:PMC8534845 | DOI:10.3390/curroncol28050347

Source: Current Oncology - October 22, 2021 Category: Cancer & Oncology Authors: Rola El Sayed Normand Blais Source Type: research